Beijing Wantai Biological Pharmacy Enterprise Co 603392.SS · CNY
Health Care · Shanghai · 🇨🇳 China
24.38
-2.09%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Wantai Biological Pharmacy Enterprise Co
Its shares trade on Shanghai under the ticker 603392.SS. It has been listed since 29 April 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.82bn and a net loss of CN¥398.3m. At that date it held total assets of CN¥14.04bn and shareholders' equity of CN¥11.86bn.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and equipment, and vaccines. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-04-29. The firm produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The firm is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Apr 2020
- Employees
- 4,016
- Website
- ystwt.com ↗
Leadership
Pay as last reported
- Mr. Zixin QiuChairman of the Board, since 2021CN¥2.0m
- Mr. Yun LuChief Financial Officer
- Ms. Zhiming JiangGeneral Manager, Director, since 2024
- Mr. Xiangzhong YeDeputy General Manager, since 2018CN¥1.5m
- Ms. Lingzhi ZhaoDeputy General Manager, since 2017CN¥1.4m
- Mr. Tao YuSecretary of the BoardCN¥1.1m
- Ms. Yamei LiDirector
- Mr. Yuchuan WangDirector
- Mr. Xuanlin CuiIndependent Director
- Mr. Huiqiang XingIndependent DirectorCN¥120,000
- Mr. Zhigang ZhaoIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 63
- Social
- 99
- Governance
- 33
- Direct emissions (scope 1)
- 21,320.69 t
- Energy emissions (scope 2)
- 41,529.13 t
- Women in the workforce
- 49%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beijing Wantai's Hecolin vaccine for hepatitis E is a key product in the Health Care sector.
- The company produces ELISA reagents and chemiluminescence reagents for in-vitro diagnostics.
- Beijing Wantai collaborates with Bio-Rad Laboratories Inc and Diagast SAS for agent products.
Weaknesses
- Beijing Wantai's reliance on Bio-Rad Laboratories Inc for agent products creates dependency.
- The company's focus on in-vitro diagnostics may limit diversification in the Health Care industry.
- Beijing Wantai's IPO in 2020 may affect long-term financial stability.
Opportunities
- Expanding vaccine production for hepatitis E in the Chinese market increases market share.
- Growing demand for in-vitro diagnostic equipment in the Health Care sector offers growth.
- Partnerships with Bio-Rad Laboratories Inc and Diagast SAS can lead to new markets.
Threats
- Competition from other in-vitro diagnostic companies in the Health Care sector.
- Regulatory changes in China could impact vaccine production and sales.
- Global supply chain disruptions may affect the availability of agent products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.